Altay Raises $37M for Oral Muscular Dystrophy Drug

Altay Therapeutics has raised $37 million to advance an oral drug targeting a genetic driver of facioscapulohumeral muscular dystrophy.

What happened

The Series A was co-led by Sound Bioventures and HealthCap, with participation from Biogen New Ventures, Fountain Healthcare Partners, Pappas Capital and Global BioAccess Fund. Altay's lead candidate, DX5057, is an oral small molecule designed to inhibit DUX4, a transcription factor associated with facioscapulohumeral muscular dystrophy. The company plans to begin a Phase I safety study in the first quarter of 2027 and intends to use the funding through Phase II proof-of-concept work. The programme remains investigational and has not yet demonstrated safety or efficacy in human patients.

Why it matters

FSHD has no approved disease-modifying therapy, creating a substantial unmet need. Altay is trying to suppress a biological driver of the disease directly rather than manage downstream symptoms. An oral therapy could also be more practical for patients than treatments requiring frequent injections or infusions.

The bigger picture

The company's broader platform uses computational modelling to identify druggable pockets on transcription factors that have historically been difficult targets. Success with DX5057 could validate both the specific programme and a wider approach to discovering medicines against challenging proteins.